CDC Labels Dominant H1N1 Viruses Subclade E, 93.4% Match Vaccine

CDC labeled the dominant H1N1 viruses subclade E, and 93.4% of 182 samples tested were well recognized by vaccine antibodies.

H1N1 flu viruses driving the current season received a new genetic label from federal health officials, though early lab testing shows this year’s shot still recognizes most of them.

The Centers for Disease Control and Prevention identified the dominant H1N1 viruses as subclade E, a designation described in the Week 45 FluView report published Nov. 20 as a newly designated alias for the D.3.1.1 family already in circulation.

Medical Daily reported that out of 182 H1N1 viruses tested since late May, 170 samples, or 93.4%, were well recognized by antibodies raised against the current vaccine strain.

Federal laboratories sorted 617 characterized H1N1 viruses into subclade E and four subgroups, with about 46.5% falling into E.1, 27.7% into E.3, 22.2% into subclade E itself, and 3.1% into E.4, while E.2 and the older D.3.1 group accounted for just three viruses, according to Medical Daily.

To evaluate the match, laboratories used antibodies from ferrets infected with the vaccine reference virus, A/Missouri/11/2025.

The match was even stronger for the other two vaccine components, as all 38 tested H3N2 viruses and all 38 tested B/Victoria viruses showed good recognition, Medical Daily noted.

Beyond vaccine compatibility, federal health officials monitored how well common treatments perform against circulating strains. Laboratory surveillance found that only eight of 781 tested viruses, or 1.0%, demonstrated a reduced response to oseltamivir, the medication sold as Tamiflu.

All eight of these instances involved H1N1 viruses that possessed two specific genetic changes. No tested samples showed reduced susceptibility to other common treatments, including peramivir, baloxavir, or zanamivir.

Earlier investigations into the G155E mutation suggested that this specific change might hinder antibody recognition in certain populations. Research using human blood samples indicated that this mutation strongly reduced antibody levels primarily among teens and young adults who already possessed high levels of existing H1N1 antibodies.

The Centers for Disease Control and Prevention said that these findings regarding human blood samples do not contradict their own ferret-based laboratory results. While ferret studies provide a standard measure for vaccine matching, they do not account for the diverse immune histories found in the general population.

Hospitals logged 11,734 lab-confirmed flu admissions during the week ending Nov. 14, marking the first week above 10,000 for the season, while seven children have died of flu so far, Medical Daily reported.

The CDC recommends a flu vaccine for everyone 6 months and older, with protection taking about two weeks to build.

As the national public health agency under the Department of Health and Human Services, the Centers for Disease Control and Prevention maintains the authority to track and classify emerging pathogens to ensure public safety.

By identifying specific genetic subclades, the agency provides the standardized nomenclature necessary for laboratories to assess how well current vaccines align with circulating strains. This surveillance role allows the agency to evaluate the effectiveness of the national vaccine program, ensuring that public health recommendations remain grounded in accurate data regarding how effectively antibodies recognize evolving viral lineages.

The next Week 45 FluView report update will be posted Nov. 30 due to the Thanksgiving holiday.

Photo of author

Health Desk

Health Desk at Archyde.

Ben Walgate Paints Mural for Friend Rew Nurse in Scarborough

Argentina Bond Yields Spike to 10.7% Over US Treasuries Amid Milei Re-election Doubts